
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics is positioned for positive revenue growth through its TRACER platform, which is expected to generate income from collaborations advancing to clinical trials in the 2030s. The company has demonstrated substantial efficacy in preclinical studies, showcasing a significant reduction in tau mRNA and protein levels, which suggests that its therapies could provide durable benefits with lower liver exposure compared to traditional methods. Additionally, the innovative NeuroShuttle technology has shown enhanced durability and safety in CNS exposure, further solidifying the potential of Voyager's gene therapy solutions in treating severe neurological diseases.
Bears say
The analysis of Voyager Therapeutics highlights several fundamental concerns that contribute to a negative outlook for the company's stock. Despite its innovative gene therapy platform and focus on severe neurological diseases, the company faces substantial financial challenges, including limited revenue generation and high operational costs associated with research and development. Furthermore, ongoing risks related to the lengthy regulatory approval processes for its therapies and potential setbacks in clinical trials may impede the company's ability to achieve sustainable growth and profitability in the near term.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares